William Blair upgraded shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Free Report) to a strong-buy rating in a research note issued to investors on Tuesday morning,Zacks.com reports.
Separately, UBS Group initiated coverage on Telix Pharmaceuticals Limited American Depositary Shares in a research note on Friday, November 15th. They issued a “buy” rating and a $21.00 price objective for the company.
Check Out Our Latest Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Trading Down 0.5 %
Featured Stories
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- 3 Small Caps With Big Return Potential
- MarketBeat Week in Review – 11/18 – 11/22
- What is Insider Trading? What You Can Learn from Insider Trading
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Tesla Investors Continue to Profit From the Trump Trade
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
